Monashee Investment Management adds Paratek Pharmaceuticals Inc (PRTK) to its portfolio

Paratek Pharmaceuticals Inc (PRTK) : Monashee Investment Management added new position in Paratek Pharmaceuticals Inc during the most recent quarter end. The investment management firm now holds 100,000 shares of Paratek Pharmaceuticals Inc which is valued at $1,305,000 , the company said in a statement filed on Aug 2, 2016 with the SEC.Paratek Pharmaceuticals Inc makes up approximately 2.00% of Monashee Investment Management’s portfolio.

Other Hedge Funds, Including , California State Teachers Retirement System boosted its stake in PRTK in the latest quarter, The investment management firm added 4,386 additional shares and now holds a total of 30,222 shares of Paratek Pharmaceuticals Inc which is valued at $394,397. Fny Managed Accounts added PRTK to its portfolio by purchasing 1,000 company shares during the most recent quarter which is valued at $13,000. Paratek Pharmaceuticals Inc makes up approx 0.01% of Fny Managed Accounts’s portfolio. Stoneridge Investment Partners added PRTK to its portfolio by purchasing 23,668 company shares during the most recent quarter which is valued at $307,684. Paratek Pharmaceuticals Inc makes up approx 0.04% of Stoneridge Investment Partners’s portfolio. Wealthtrust-arizona added PRTK to its portfolio by purchasing 100 company shares during the most recent quarter which is valued at $1,292. Cutler Group Lp added PRTK to its portfolio by purchasing 9,887 company shares during the most recent quarter which is valued at $130,508. Paratek Pharmaceuticals Inc makes up approx 0.01% of Cutler Group Lp’s portfolio.

Paratek Pharmaceuticals Inc opened for trading at $13.09 and hit $13.235 on the upside on Monday, eventually ending the session at $13.15, with a gain of 1.00% or 0.13 points. The heightened volatility saw the trading volume jump to 1,27,705 shares. Company has a market cap of $298 M.

Many Wall Street Analysts have commented on Paratek Pharmaceuticals Inc. Company shares were Reiterated by H.C. Wainwright on Jun 17, 2016 to “Buy”, Firm has raised the Price Target to $ 34 from a previous price target of $31 .Robert W. Baird Initiated Paratek Pharmaceuticals Inc on May 13, 2016 to “Outperform”, Price Target of the shares are set at $30.

Paratek Pharmaceuticals Inc. (Paratek) formerly Transcept Pharmaceuticals Inc. is a pharmaceutical company focused on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry. Paratek’s two antibacterial product candidates are omadacycline and sarecycline. Omadacycline is a broad-spectrum antibiotic for use as an empiric monotherapy for community-acquired bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) community-acquired bacterial pneumonia (CABP) and urinary tract infections (UTI). Sarecycline is in Phase III clinical trial stage for the treatment of acne and omadacycline has completed Phase III clinical trial for treatment of complicated skin and skin structure infection (cSSSI) and Phase II clinical trials for the treatment of ABSSSI and CABP. Sarecycline is a once-daily tetracycline-derived compound designed for use in the treatment of acne and rosacea.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Paratek Pharmaceuticals Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Paratek Pharmaceuticals Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.